Shi Y J, Han Y, Zhang X F, Xi R, Bai H, Wu T
Department of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):956-959. doi: 10.3760/cma.j.cn121090-20240311-00089.
The onset of myasthenia gravis (MG) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) seriously threatens the survival of patients, since it is acute, and is prone to rapid progression. Two patients with acute myeloid leukemia (AML), who had undergone allo-HSCT developed shortness of breath, and gradually developed cervical weakness and dyspnea. The acetylcholine receptor (AChR) antibody and neostigmine test enabled the diagnosis of MG. The condition of the patients improved after treatment with pyridostigmine bromide, glucocorticoids and rituximab.
异基因造血干细胞移植（allo-HSCT）后发生重症肌无力（MG）严重威胁患者生存，因为其发病急，且易于快速进展。两名接受allo-HSCT的急性髓系白血病（AML）患者出现气短，并逐渐发展为颈部无力和呼吸困难。乙酰胆碱受体（AChR）抗体及新斯的明试验确诊为MG。患者经溴吡斯的明、糖皮质激素及利妥昔单抗治疗后病情改善。
